James Callaway Net Worth

James Callaway biography

James Eric Callaway, Ph.D., is Independent Director of the company. He joins the Xenetic Board of Directors with over 30 years of experience in the execution of product development operations for biotherapeutics. Dr. Callaway has an established track record of achievement against challenging technologies and aggressive project timelines. He currently serves as a Corporate Strategy Consultant at Callaway Innovations. Dr. Callaway is a seasoned CEO within the venture-backed biotech community and over the course of his career he has built and operated two companies, transforming each from research companies to clinical stage operating entities. Prior to these efforts, Dr. Callaway held multiple senior leadership positions at Elan Pharmaceuticals, including simultaneously acting as Head of Development and overseeing the complex partnership with Wyeth Pharmaceuticals in the Alzheimer’s disease immunotherapy program. He has developed antibodies for a wide-range of therapeutic applications over the past two decades, including treatments of multiple sclerosis (Tysabri®: pharmaceutical development), Alzheimer’s disease (bapineuzumab: Program Executive), and blood-brain barrier transport, and has worked with the United Stated Food and Drug Administration on multiple orphan drug development programs.

What's James Callaway's mailing address?

James's mailing address filed with the SEC is 945, Concord Street, Framingham, Middlesex County, Massachusetts, 01701, United States.

What does Xenetic Biosciences Inc do?

xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid

Xenetic Biosciences Inc executives and stock owners

Xenetic Biosciences Inc executives and other stock owners filed with the SEC include:

• Jeffrey F. Eisenberg Esq.,
  CEO, Pres & Director
• James F. Parslow,
  CFO, COO & Corp. Sec.
• Dr. Curtis A. Lockshin,
  Chief Scientific Officer
• Colin Hill,
  Treasurer, Secretary, Director
• Grigory Borisenko,
  Director
• Adam Logal,
  Independent Director
• Dmitry Genkin,
  Independent Director
• James Callaway,
  Independent Director
• Roger Kornberg,
  Director
• Artur Isaev,
  Director
• Firdaus Dastoor,
  Director
• Timothy Cote,
  Director
• Curtis Lockshin,
  Chief Scientific Officer
• James Parslow,
  Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
• Jeffrey Eisenberg,
  Chief Executive Officer, Chief Operating Officer, Director
• Moshe Mizrahy,
  Director
• Darlene M Deptula Hicks,
  Director
• Alexey Andreevich Vinogradov,
  Director
• Michael Scott Maguire,
  CEO
• Edward J. Jr Benz,
  Director